{"id":"refresh-optive","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Refresh Optive","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:40:35.644122+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:40:41.592308+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Refresh Optive","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:40:41.908199+00:00"}},"_dailymed":{"setId":"326cb5d6-c784-404f-9a13-6d69262dda6e","title":"REFRESH OPTIVE MEGA-3 PF (CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80) SOLUTION/ DROPS [ALLERGAN, INC.]"},"_scrapedAt":"2026-03-28T00:04:33.609Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:40:44.198840+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07284381","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-12-15","conditions":"Dry Eye Disease","enrollment":250},{"nctId":"NCT04125134","phase":"PHASE4","title":"Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2019-10-03","conditions":"Dry Eye","enrollment":36},{"nctId":"NCT06439394","phase":"","title":"An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-06-17","conditions":"Dry Eye","enrollment":52},{"nctId":"NCT06443775","phase":"","title":"An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-06-17","conditions":"Dry Eye","enrollment":47},{"nctId":"NCT06975891","phase":"PHASE4","title":"Performance of Systane PRO Versus Refresh Optive Mega-3","status":"RECRUITING","sponsor":"Scripps Poway Eyecare and Optometry","startDate":"2025-05-15","conditions":"Dry Eye","enrollment":35},{"nctId":"NCT01207752","phase":"NA","title":"The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Southern California College of Optometry at Marshall B. Ketchum University","startDate":"2010-09","conditions":"Meibomian Gland Dysfunction","enrollment":69},{"nctId":"NCT05705518","phase":"PHASE4","title":"Artificial Tears, Tear Lipids and Tear Film Dynamics","status":"COMPLETED","sponsor":"University of California, Berkeley","startDate":"2023-01-30","conditions":"Dry Eye","enrollment":81},{"nctId":"NCT03380624","phase":"PHASE4","title":"Tear Lipid Layer Thickness With Emollient Eye Drops","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2017-03-01","conditions":"Dry Eye Syndromes","enrollment":21},{"nctId":"NCT02776670","phase":"NA","title":"Clinical Outcomes Following Treatment With SYSTANE® BALANCE","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-07-29","conditions":"Dry Eye","enrollment":308},{"nctId":"NCT02121847","phase":"PHASE4","title":"Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-04-03","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT02280473","phase":"PHASE3","title":"A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-11-13","conditions":"Dry Eye Syndromes","enrollment":188},{"nctId":"NCT01459588","phase":"PHASE3","title":"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10-01","conditions":"Dry Eye Syndromes","enrollment":315},{"nctId":"NCT02818816","phase":"PHASE4","title":"Preoperative Brimonidine on IOP of Patients Undergoing RALP","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-02-29","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT02553772","phase":"PHASE3","title":"A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-01-06","conditions":"Dry Eye Syndromes","enrollment":242},{"nctId":"NCT00812721","phase":"NA","title":"Tears Substitutions and Their Effects on Higher Order Aberrometery","status":"WITHDRAWN","sponsor":"Gina Rogers","startDate":"2009-01","conditions":"Dry Eye Syndrome","enrollment":""},{"nctId":"NCT01664949","phase":"PHASE3","title":"A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-01","conditions":"Dry Eye Disease","enrollment":460},{"nctId":"NCT00691197","phase":"PHASE2, PHASE3","title":"Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-03","conditions":"Ametropia","enrollment":246}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Refresh Optive","genericName":"Refresh Optive","companyName":"Ohio State University","companyId":"ohio-state-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:40:44.198840+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}